Abstract
IgE is a key mediator to activate mast cell, contributing to the pathogenesis of CSU. Atopy is a predisposing factor of CSU, where omalizumab is a widely used monoclonal antibody to control symptoms via capturing serum free IgE. However, the role of free IgE in CSU is not well evaluated. The present study evaluated the clinical relevance of serum free IgE in CSU.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
